Astrana Health, Inc. (ASTH) 股票分析

公司概述

Astrana Health, Inc. operates as a healthcare management company delivering medical care services across the United States through three distinct business segments: Care Partners, Care Delivery, and Care Enablement, which collectively provide care coordination services to patients, families, and primary care physicians. This entity functions within the broader Healthcare sector, specifically categorized under the Medical Care Facilities industry, positioning it as a key player in the organization and administration of medical services. The company demonstrates significant scale with a total market capitalization of $1.57 billion, annual revenue reaching $3.18 billion, and an employee base of 3,000 individuals. These valuation and revenue figures indicate that Astrana Health commands a substantial presence in the medical care market, reflecting a large operational footprint that supports its diverse service offerings.

财务健康

The company reported a trailing twelve-month revenue of $3.18 billion, with a corresponding net income of $22.49 million and an EBITDA of $143.87 million, highlighting a substantial gap between top-line revenue and bottom-line profit that reveals a high cost structure comprising operating expenses and taxes. Despite this revenue-to-profit compression, the firm generated free cash flow of $227.95 million, indicating robust operational cash generation that provides the necessary financial flexibility for capital allocation or debt servicing. Profitability metrics show a gross margin of 10.7%, an operating margin of 1.9%, and a profit margin of 0.7%, where the low operating and profit margins suggest that a large portion of revenue is consumed by direct costs and overhead before reaching the bottom line. On the balance sheet, Astrana Health holds $429.59 million in cash against $1.08 billion in debt, resulting in a debt-to-equity ratio of 193.10, which characterizes the company as highly leveraged rather than conservative. Liquidity is supported by a current ratio of 1.40, suggesting the firm possesses sufficient current assets to cover its short-term liabilities without immediate distress. Return on equity stands at 4.5% while return on assets is 3.4%, revealing that management effectiveness in generating returns on shareholder capital and total assets remains modest relative to the company's leverage levels.

估值评估

Valuation metrics present a wide disparity between historical and future expectations, with a trailing P/E ratio of 61.37 compared to a forward P/E of 9.44, implying that the market anticipates a significant expansion in earnings that would otherwise compress the current multiple. The price-to-book ratio is recorded at 1.77, indicating that the stock trades at a moderate premium over its net asset value, suggesting investors are paying for growth prospects or brand intangibles rather than purely book value. Alternative valuation measures include a price-to-sales ratio of 0.49 and an EV/EBITDA of 12.68, which suggest the stock is priced at a fraction of its sales revenue while maintaining an enterprise value relative to earnings that is lower than the trailing P/E multiple. Regarding price volatility, the stock has traded between a 52-week high of $34.80 and a 52-week low of $18.08, meaning the current price sits within this established trading range and reflects market sentiment fluctuations. The beta of 0.77 indicates that the stock's price volatility is lower than the broader market, suggesting it may act as a less volatile component within a diversified portfolio during market swings.

Growth & Income

Revenue growth accelerated significantly with a year-over-year increase of 42.9%, whereas earnings growth is currently N/A, implying that profitability has not yet expanded at the same pace as revenue, which often occurs during periods of market share acquisition or cost restructuring. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings are retained within the business to fund operations and growth initiatives rather than being distributed to shareholders. This reinvestment strategy aligns with the company's high revenue growth rate, prioritizing internal expansion over immediate income distribution to stakeholders. The overall growth and income profile reflects a high-growth, non-yielding equity where capital appreciation potential is theoretically tied to future earnings realization rather than current income distributions.